Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
S Afr Med J ; 114(5)2024 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-39041479

RESUMEN

In September 2015, South Africa (SA) and 192 countries adopted Agenda 2030, which included the Sustainable Development Goals. With a mere 6 years to go before 2030, it is useful to understand what progress SA is making towards their attainment. In this short report, we assess progress towards meeting the maternal mortality target, globally and in SA. The maternal mortality ratio that countries are expected to reach is no more than 70 deaths per 100 000 live births. A range of sources is used to show progress, with an emphasis on the reports of the National Committee on Confidential Enquiries into Maternal deaths, which reports on the number of maternal deaths in health facilities, together with reasons for these deaths and recommendations to reduce preventable mortality.


Asunto(s)
Mortalidad Materna , Desarrollo Sostenible , Humanos , Mortalidad Materna/tendencias , Sudáfrica/epidemiología , Femenino , Embarazo , Objetivos , Servicios de Salud Materna/organización & administración
2.
AIDS ; 15(14): 1857-63, 2001 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-11579249

RESUMEN

OBJECTIVES: To document the impact of tuberculosis and HIV-1 on maternal mortality. DESIGN: Prospective study, 1997 and 1998; retrospective analysis, 1996. PARTICIPANTS: Known maternal deaths, defined as the death of a mother within a year post-delivery, were studied in Durban, KwaZulu Natal. The HIV-1 status, presence of tuberculosis, maternal clinical features and perinatal outcomes were documented. The overall as well as HIV-1 and tuberculosis-specific maternal mortality rates for the hospital were calculated. The attributable fraction of deaths as a result of HIV-1 was calculated in the overall group and in those with tuberculosis co-infection. RESULTS: A total of 50 518 deliveries and 101 maternal deaths were recorded. Of the deaths, 29.7% (30/101) were HIV-1 infected. The overall mortality rate was 200/100 000; for HIV-1-infected women this was 323.3/100 000, HIV-1-negative mothers, 148.6/100 000 live births. The attributable fraction of overall deaths as a result of HIV-1 was 15.9% Fourteen of the 15 mothers with tuberculosis were HIV-1 co-infected. The mortality rate for tuberculosis and HIV-1 co-infection was 121.7/1000; for tuberculosis without HIV-1 co-infection, 38.5/1000. Fifty-four per cent of maternal deaths caused by tuberculosis were attributable to HIV-1 infection. Thirty-five per cent of maternal deaths were associated with stillbirths; perinatal outcomes were no different between groups of mothers with tuberculosis, HIV-1 or neither infection. CONCLUSION: Tuberculosis and HIV-1 are emerging as significant contributors to maternal mortality in KwaZulu Natal. Any attempt to improve maternal health must also include careful screening and investigation for tuberculosis in high-risk pregnant women.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/mortalidad , Infecciones por VIH/mortalidad , VIH-1 , Tuberculosis Pulmonar/mortalidad , Infecciones Oportunistas Relacionadas con el SIDA/microbiología , Adolescente , Adulto , Femenino , Anticuerpos Anti-VIH/sangre , Infecciones por VIH/complicaciones , VIH-1/inmunología , Humanos , Mortalidad Materna , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Embarazo , Complicaciones Infecciosas del Embarazo/microbiología , Complicaciones Infecciosas del Embarazo/mortalidad , Complicaciones Infecciosas del Embarazo/virología , Sudáfrica/epidemiología , Tuberculosis Pulmonar/diagnóstico
3.
J Obstet Gynaecol Res ; 27(3): 111-5, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11561825

RESUMEN

We present a case of isolated vulval Langerhans cell histiocytosis (LCH) that was initially treated with an excision biopsy but recurred 2 months later. Local vulval radiotherapy resulted in complete resolution of the lesion and there was no evidence of recurrence after 24 months of follow-up.


Asunto(s)
Histiocitosis de Células de Langerhans/diagnóstico , Enfermedades de la Vulva/diagnóstico , Biopsia , Femenino , Histiocitosis de Células de Langerhans/patología , Histiocitosis de Células de Langerhans/terapia , Humanos , Persona de Mediana Edad , Radioterapia , Enfermedades de la Vulva/patología , Enfermedades de la Vulva/terapia
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda